Connect with us

Hi, what are you looking for?

press release

These stocks are on the radar after Biogen-Eisai surprise – Press Release

aapharma 17

  • One of the most viewed Alzheimer’s therapies in the clinic, Biogen Inc BIIBEisai Limited ESALY Experimental lecanemab reduced clinical decline on the scale by 27% compared to placebo at 18 months in early-stage Alzheimer’s.
  • In July 2022, the FDA accepted the expedited submission for lecanemab and granted priority review. The PDUFA date is January 6, 2023.
  • Also read: This analyst believes Biogen’s lecanemab data is not a “slam dunk” for full CMS approval.
  • Several stocks related to Alzheimer’s programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer’s space.

Eli Lilly and Co LLY – Market capitalization: 295 billion US dollars.

  • Its anti-amyloid beta donamemab is expected to have a positive readthrough in the first half of 2023.
  • in a (n exploratory analysisthe first analysis found that patients receiving donanemab showed a more significant change in amyloid plaque levels, which was “highly associated with less cognitive decline.”

Roche Holding AG RHHBY-Market capitalization: $250 billion.

  • In addition to crenezumab, Roche is also evaluating gantenerumab in collaboration with MorphoSys AG MOR in autosomal dominant Alzheimer’s disease, as well as for the prevention of sporadic Alzheimer’s disease and for the treatment of early-stage Alzheimer’s in late-stage studies.
  • received gantenerumab FDA Breakthrough Designation.

Novo Nordisk A/S NVO– Market capitalization: 215 billion US dollars.

  • Orally administered semaglutide is currently in Phase 3 trials for early Alzheimer’s disease and is expected to be completed 2025.

Cassava Sciences Inc SAVA – Market capitalization: $1.85 billion

  • Simufilam, Cassava’s Alzheimer’s candidate, is a small molecule (oral) drug that restores the normal form and function of the altered filamin A protein in the brain.
  • Entangled in controversy over made-up dates for the candidate. Recently, the Journal of Prevention of Alzheimer’s Disease received no evidence of this Support data tampering allegations.

Prothena Corporation Plc PRTA – Market capitalization: 1.5 billion US dollars.

Source Story here

You May Also Like

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.


State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

Health News

The cosmetic and facial plastic surgery practice is hosting a grand opening celebration and ribbon cutting for its new Chattanooga state-of-the-art location.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...